Lisata Therapeutics to be Acquired by Kuva Labs for $5.00 Cash Plus $1.00 Contingent Value Right

summarizeSummary

Lisata Therapeutics has entered into a definitive agreement to be acquired by Kuva Labs for $5.00 per share in cash and a contingent value right (CVR) worth up to an additional $1.00 per share, pending a regulatory milestone.

check_boxKey Events

• Definitive Merger Agreement

  Lisata Therapeutics will be acquired by Kuva Labs Inc. through a tender offer and subsequent merger, as announced in a definitive agreement dated March 6, 2026.

• Acquisition Consideration

  Shareholders will receive $5.00 per common share in cash at closing, plus one non-tradeable Contingent Value Right (CVR) for a potential additional $1.00 per share.

• Contingent Value Right (CVR) Details

  The CVR is contingent on a New Drug Application (NDA) filing or formal acceptance for review by the FDA or any governmental authority for Lisata's certepetide product candidate within seven years of the closing date. Kuva Labs will use commercially reasonable efforts to achieve this milestone, but there is no guarantee of payment.

• Board Recommendation

  Lisata's Board of Directors unanimously approved the transaction and recommends that stockholders accept the offer and tender their shares.

auto_awesomeAnalysis

This filing announces a definitive merger agreement for Lisata Therapeutics to be acquired by Kuva Labs Inc. Shareholders will receive $5.00 per share in cash at closing, which is slightly above the 52-week high of $4.89. Additionally, they will receive a non-tradeable Contingent Value Right (CVR) for a potential additional $1.00 per share upon the achievement of a specific regulatory milestone related to its certepetide product candidate within seven years. The total potential consideration of $6.00 per share represents a substantial premium over the current stock price and the company's market valuation. The board has unanimously approved the transaction, offering a clear exit for shareholders with potential upside tied to future drug development success. This follows the extension of a term sheet for acquisition disclosed on February 27, 2026, now culminating in a definitive agreement.